Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) by Marre, M et al.
 
© 2009 The Authors.
 
268
 
Journal compilation © 2009 Diabetes UK. 
 
Diabetic Medicine
 
, 
 
26
 
, 268–278
 
DIABETIC
 
Medicine
DOI: 10.1111/j.1464-5491.2009.02666.x
 
Blackwell Publishing Ltd
 
Original Article: Treatment
Liraglutide, a once-daily human GLP-1 analogue, added 
to a sulphonylurea over 26 weeks produces greater 
improvements in glycaemic and weight control compared 
with adding rosiglitazone or placebo in subjects with 
Type 2 diabetes (LEAD-1 SU)
 
M. Marre, J. Shaw,* M. Brändle,† W. M. W. Bebakar,‡ N. A. Kamaruddin,§ J. Strand,¶ 
M. Zdravkovic,** T. D. Le Thi** and S. Colagiuri†† on behalf of the LEAD-1 SU study group
 
Service d’Endocrinologie Diabétologie Nutrition, Groupe Hospitalier Bichat
 
—
 
Claude Bernard, Paris, France, *International Diabetes Institute, Melbourne, Australia, 
†Division of Endocrinology, Diabetes and Osteology, Kantonsspital St Gallen, Switzerland, ‡Department of Medicine, Hospital Universiti Sains, Malaysia, Kelantan, 
§Department of Medicine, National University of Malaysia (UKM), Kuala Lumpur, Malaysia, ¶Oulun Diakonissalaitos, Oulu, Finland, **Novo Nordisk A/S, Bagsvaerd, 
Denmark and ††Institute of Obesity, Nutrition and Exercise, University of Sydney, Australia
 
Accepted 20 December 2008
 
Abstract
 
Aim
 
To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all 
 
n
 
 
 
≥
 
 228) or
placebo (
 
n
 
 
 
=
 
 114) with glimepiride (2–4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes.
 
Methods
 
In total, 1041 adults (mean 
 
±
 
 
 
SD
 
), age 56 
 
±
 
 10 years, weight 82 
 
±
 
 17 kg and glycated haemoglobin (HbA
 
1c
 
)
8.4 
 
±
 
 1.0% at 116 sites in 21 countries were stratified based on previous oral glucose-lowering mono : combination
therapies (30 : 70%) to participate in a five-arm, 26-week, double-dummy, randomized study.
 
Results
 
Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA
 
1c
 
 from baseline, (
 
−
 
1.1%, baseline 8.5%) com-
pared with placebo (+0.2%, 
 
P
 
 
 
<
 
 0.0001, baseline 8.4%) or rosiglitazone (
 
−
 
0.4%, 
 
P
 
 
 
<
 
 0.0001, baseline 8.4%) when added
to glimepiride. Liraglutide 0.6 mg was less effective (
 
−
 
0.6%, baseline 8.4%). Fasting plasma glucose decreased by week 2,
with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline
9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, 
 
P
 
 
 
<
 
 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease
(rosiglitazone, 
 
P
 
 
 
<
 
 0.006, baseline 9.9 mmol/l). Decreases in postprandial plasma glucose from baseline were greater
with liraglutide 1.2 or 1.8 mg [
 
−
 
2.5 to 
 
−
 
2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo
(
 
−0
 
.4 mmol/l, 
 
P
 
 
 
<
 
 0.0001, baseline 12.7 mmol/l) or rosiglitazone (
 
−
 
1.8 mmol/l, 
 
P
 
 
 
<
 
 0.05, baseline 13.0 mmol/l).
Changes in body weight with liraglutide 1.8 mg (
 
−
 
0.2 kg, baseline 83.0 kg), 1.2 mg (+0.3 kg, baseline 80.0 kg) or placebo
(
 
−
 
0.1 kg, baseline 81.9 kg) were less than with rosiglitazone (+2.1 kg, 
 
P
 
 
 
<
 
 0.0001, baseline 80.6 kg). Main adverse events
for all treatments were minor hypoglycaemia (
 
<
 
 10%), nausea (
 
<
 
 11%), vomiting (
 
<
 
 5%) and diarrhoea (
 
< 
 
8%).
 
Conclusions
 
Liraglutide added to glimepiride was well tolerated and provided improved glycaemic control and favour-
able weight profile.
Diabet. Med. 26, 268–278 (2009)
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Introduction
 
Most drugs that target Type 2 diabetes (T2D) also cause weight
gain or hypoglycaemia, or both, with the risk increasing with
combination therapy. Glucagon-like peptide-1 (GLP-1)-based
therapies stimulate insulin secretion and reduce glucagon
secretion only during hyperglycaemia. GLP-1 also slows gastric
emptying and reduces appetite [1].
Although American Diabetes Association (ADA)/European
Association for the Study of Diabetes (EASD) guidelines
recommend lifestyle and metformin as initial therapy for
T2D [2], sulphonylureas are used widely, particularly when
metformin or thiazolidinediones are not tolerated. Glycaemic
control eventually deteriorates with sulphonylureas while
hypoglycaemia and weight gain are common [3]. Incretin
therapy improves glycaemic control with low hypoglycaemic
risk, while delayed gastric emptying and reduced appetite can
reduce weight [1,4].
Liraglutide is a once-daily human GLP-1 analogue with
97% linear amino-acid sequence homology to human GLP-1
[5] and half-life of 13 h after subcutaneous administration that
produces 24-h blood glucose control [6]. Liraglutide mono-
therapy for 14 weeks reduced glycated haemoglobin (HbA
 
1c
 
)
by 1.7% and fasting plasma glucose (FPG) by 3.4 mmol/l
without causing hypoglycaemia, along with weight loss (~3 kg)
compared with placebo [7]. Improvements in pancreatic B-cell
function [7–9] and blood pressure [7], along with decreased
glucagon secretion [7,10], also occurred. As part of the phase 3
programme [the Liraglutide Effect and Action in Diabetes
(LEAD) programme] with liraglutide in 
 
>
 
 4000 subjects with
T2D as monotherapy or in combination therapy, this 26-week
trial examined liraglutide plus glimepiride compared with
either placebo or rosiglitazone added to glimepiride on
glycaemic control and body weight.
 
Subjects and methods
 
Study participants
 
Inclusion criteria: T2D treated with oral glucose-lowering
agents (OGLAs) for 
 
≥
 
 3 months; 18–80 years of age; HbA
 
1c
 
7.0–11.0% (previous OGLA monotherapy) or 7.0–10.0%
(previous OGLA combination therapy); body mass index
(BMI) 
 
≤
 
 45.0 kg/m
 
2
 
. Exclusion criteria: used insulin within
3 months, impaired liver or renal function, uncontrolled
hypertension (
 
≥
 
  180/100  mmHg), cancer or used any drugs
apart from OGLAs likely to affect glucose concentrations.
Subjects provided written informed consent. The study was
conducted in accordance with good clinical practice guidelines
and approved by independent ethics committees.
 
Study design
 
The study was a 26-week, double-blind, double-dummy,
randomized, active-control, five-armed parallel (116 sites in
21 countries, primarily Europe and Asia) trial enrolling 1041
subjects (1–37 subjects per centre), all receiving glimepiride (2–
4 mg/day) in combination with (Fig. 1):
• one of three liraglutide doses [0.6, 1.2 or 1.8 mg, injected
subcutaneously (Novo Nordisk, Bagsvaerd, Denmark) and
rosiglitazone placebo];
• liraglutide placebo and rosiglitazone placebo;
• liraglutide placebo and rosiglitazone 4 mg/day (rosiglitazone;
Avandia™; GlaxoSmithKline, London, UK).
FIGURE 1 Overview of trial design and 
treatment arms.
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The doses of rosiglitazone and glimepiride used were determined
by the highest doses approved in all participating counties.
After discontinuing previous OGLAs except glimepiride, separate
2-week titration and maintenance periods with glimepiride
(open-label) preceded randomization (Fig.  1). Subjects were
stratified according to previous treatment (monotherapy or
combination therapy). After randomization, 2-week treatment
titration and 24-week treatment (maintenance) phases (Fig. 1)
were completed. Liraglutide was up-titrated weekly in 0.6-mg
increments until allocated doses were reached. Glimepiride
could be adjusted between 2 and 4 mg/day in case of hypoglycaemia
or other adverse events (AEs), while other drug doses were
fixed. Liraglutide (active and placebo) was supplied in 3-ml
pre-filled pens with 31G needles (Novo Nordisk). Subjects
were encouraged to inject liraglutide into the upper arm, thigh
or  abdomen at the same time each day. Rosiglitazone and
glimepiride were taken in the morning or with the first meal.
 
Study measurements
 
Efficacy
 
The primary endpoint was change from baseline HbA
 
1c
 
 after
26 weeks of treatment. Secondary endpoints included: percentages
of subjects reaching HbA
 
1c
 
 (
 
<
 
 7.0%, 
 
≤
 
  6.5%), FPG (5.0 to
 
≤ 
 
7.2 mmol/l) and postprandial plasma glucose (PPG; 10.0 mmol/l)
targets [11–13]; changes in body weight, FPG, mean PPG, indices
of pancreatic B-cell function [pro-insulin  :  insulin ratio and
homeostasis model assessment (HOMA)-B], HOMA-insulin
resistance (HOMA-IR) and blood pressure (BP).
HbA
 
1c
 
 was measured centrally (MDS Pharma Services, King
of Prussia, PA, USA) by high performance liquid chromatography
while plasma glucose (PG) was self-measured using MediSense®
glucose meters (Abbott Diagnostics Inc., Abbott Park, IL, USA).
Insulin and C-peptide were measured by chemiluminescence, pro-
insulin by ELISA, while glucagon was measured in aprotinin-
treated plasma by radioimmunoassay. The proinsulin : insulin
ratio was calculated from fasting insulin and fasting proinsulin.
HOMA-B and HOMA-IR were both calculated from FPG
and fasting insulin. Samples measured centrally were collected
and transported according to detailed procedures in the MDS
Pharma Services manual. Samples stored at ambient temperature
were shipped by courier to the central laboratory on the same
day as collection, while frozen samples were shipped every 3 weeks.
 
Safety
 
Safety variables included hypoglycaemic episodes based on PG
levels (
 
<
 
 3.1 mmol/l), liraglutide antibodies including cross-
reacting and neutralizing antibodies, tolerability (gastrointestinal
complaints) and pulse. AEs, vital signs, electrocardiogram (ECG),
biochemical and haematology measures including calcitonin
were also monitored. Self-treated hypoglycaemic episodes were
classified as minor, while those requiring third-party assistance
were considered major. Serum antibodies against liraglutide
were measured by radioimmunoprecipitation assay.
 
Statistical analyses
 
All efficacy and safety analyses were based on intent-to-treat
criteria, defined as subjects who were exposed to 
 
≥
 
 1 dose of
trial product(s). Efficacy endpoints were analysed by 
 
ANCOVA
 
with treatment, country and previous glucose-lowering treatment
as fixed effects and baseline values as covariates. Missing data
were imputed by last observation carried forward (LOCF).
Sample size calculations were based on predicted HbA
 
1c
 
 and
body weight after trial completion. As the three liraglutide +
glimepiride groups were to be compared with both rosigli-
tazone + glimepiride and glimepiride monotherapy, two calcula-
tions were performed. These sample size calculations assumed
a standard deviation of 1.2% of HbA
 
1c
 
, the non-inferiority/
superiority margin vs. active control was set to 0.4% and the
difference to detect (superiority vs. placebo) was set to 0.5%.
For body weight, a coefficient of variation of 3% (based on
phase 2a trials for liraglutide) and a difference to detect of 3%
were assumed. A combined power (calculated as the product of
the marginal powers for HbA
 
1c
 
 and body weight) of at least
85% was required. These calculations indicated that at least
168 and 81 patients completing the study would be needed for
the combination and glimepiride monotherapy groups, respectively.
Assuming a drop-out rate of 25%, targets for randomization
were 228 in each of the combination therapy groups and 114 in
the placebo group (total 
 
n 
 
=
 
 1026).
To protect against Type 1 errors, HbA
 
1c
 
 was analysed using
hierarchical testing for descending doses of liraglutide. First,
superiority of liraglutide 1.8 mg to placebo was tested and,
only if superior to placebo, non-inferiority to rosiglitazone
was tested. If non-inferiority was obtained, superiority to
rosiglitazone for liraglutide 1.8 mg was tested and superiority to
placebo for liraglutide 1.2 mg was tested. If superiority was
confirmed, non-inferiority to rosiglitazone would be tested and
so on (i.e. testing sequence was stopped when hypotheses could
not be rejected). Superiority was concluded when upper
limits of two-sided 95% confidence intervals (CIs) for treatment
differences were below 0%; non-inferiority was concluded if
these values were 
 
<
 
 0.4%; for secondary endpoints, Type 1
errors were controlled by estimating simultaneous CIs using
Dunnett’s method.
Proportions of subjects achieving HbA
 
1c
 
  (HbA
 
1c
 
 
 
<
 
 7.0%,
and 
 
≤
 
  6.5%) and FPG (5.0 
 
≤
 
 FPG 
 
≤
 
  7.2  mmol/l) targets [13]
were compared between treatments using logistic regression
with allocated treatment and baseline values as covariates. Chi-
square analyses assessed differences in treatments for percent-
ages of subjects achieving no, one, two or three PPG values
 
<
 
 10 mmol/l [13]. Hypoglycaemic episodes were analysed under
the assumption that number per subject were negatively
binomially distributed using a generalized linear model, including
treatment and country as fixed effects. Other safety data were
compared by descriptive statistics. Values for descriptive statistics
are expressed as means 
 
±
 
 
 
SD
 
, while 
 
ANCOVA
 
 results are expressed
as least square means 
 
±
 
 SEM or with 95% CI unless otherwise
noted. Significance levels were set to 5% for two-sided tests and
2.5% for one-sided tests.
 
Results
 
Disposition and demographics
 
The treatment groups were well balanced (Table 1). Of 1712
subjects screened, 1041 were randomized and 1040 were exposed
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to trial drugs; 147 subjects (14.1%) withdrew (Fig.  2).
Withdrawals were higher with placebo (27%) and rosiglita-
zone treatment (16%) compared with liraglutide 0.6 mg (11%),
liraglutide 1.2  mg (14%) and liraglutide 1.8  mg (9%)
treatment. Thirty-eight subjects (3.7%) withdrew as a result
of AEs (Fig. 2).
 
Efficacy
 
HbA
 
1c
 
HbA
 
1c
 
 decreased rapidly with all doses of liraglutide when added
to glimepiride compared with either rosiglitazone or placebo
(i.e. glimepiride monotherapy), irrespective of previous therapy.
Table 1 Demographic characteristics of study participants
Liraglutide 
0.6 mg (n = 233)
Liraglutide 
1.2 mg (n = 228)
Liraglutide 
1.8 mg (n = 234)
Placebo 
(n = 114)
Rosiglitazone 
(n = 232)
Male : female (%) 54 : 46 45 : 55 53 : 47 47 : 53 47 : 53
Age (years) 55.7 ± 9.9 57.7 ± 9.0 55.6 ± 10.0 54.7 ± 10.0 56.0 ± 9.8
Duration of diabetes (years) 6.5 (4.0,10.2) 6.7 (4.0,10.7) 6.5 (3.7,10.5) 6.5 (4.5,10.6) 6.6 (4.3,10.7)
Previous on mono : combi (%) 30 : 70 31 : 69 27 : 73 32 : 68 32 : 68
FPG (mmol/l) 10.0 ± 2.4 9.8 ± 2.7 9.7 ± 2.4 9.5 ± 2.0 9.9 ± 2.5
HbA1c (%) 8.4 ± 1.0 8.5 ± 1.1 8.5 ± 0.9 8.4 ± 1.0 8.4 ± 1.0
Diabetic retinopathy (%) 17.2 14.9 12.0 13.2 16.4
Hypertension (%) 69.1 68.0 69.7 64.9 66.8
BMI (kg/m2) 30.0 ± 5.0 29.8 ± 5.1 30.0 ± 5.1 30.3 ± 5.4 29.4 ± 4.8
Weight (kg) 82.6 ± 17.7 80.0 ± 17.1 83.0 ± 18.1 81.9 ± 17.1 80.6 ± 17.0
Systolic blood pressure (mmHg) 131 ± 16 133 ± 15 132 ± 16 131 ± 15.3 133 ± 15
Data are mean ± SD and percentages, except for duration of diabetes, where data are median, 25th and 75th percentile.
BMI, body mass index; FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; mono : combi, previous treatment with either 
monotherapy or combination therapy; SD, standard deviation.
FIGURE 2 Flow of patients through the study.
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The greatest decreases occurred with liraglutide 1.2 and 1.8 mg
(Fig. 3a–c). After 26 weeks, HbA
 
1c
 
 decreased by 1.1% from
baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg,
respectively, compared with either placebo (+0.2%) or rosigli-
tazone (
 
−
 
0.4%) (Fig. 3d). Estimated treatment differences and
95% CIs to placebo were: liraglutide 1.8 mg: −1.4% (1.6, −1.1);
liraglutide 1.2 mg: −1.3% (1.5, −1.1); liraglutide 0.6 mg: −0.8%
(−1.1, −0.6); rosiglitazone: −0.7% (−0.9, −0.4). All liraglutide
doses were superior to placebo (P < 0.0001), while the two higher
liraglutide doses were superior to rosiglitazone (P < 0.0001).
Liraglutide 0.6 mg was non-inferior to rosiglitazone. Rosiglitazone
also was superior to placebo (P < 0.0001).
HbA1c decreases were greater for subjects who entered from
monotherapy compared with combination therapy (Fig. 3d).
However, because the increase with placebo was higher for
individuals entering on combination therapy (0.7 vs. 0.23%),
FIGURE 3 Mean glycated haemoglobin (HbA1c) by treatment and week (intent-to-treat population with last observation carried forward): (a) overall 
population; (b) previously on monotherapy; or (c) previously on combination therapy; (d) mean changes in HbA1c from baseline after 26 weeks of 
treatment. Keys: (a–c) liraglutide 0.6 mg: grey dotted line with squares; liraglutide 1.2 mg: black solid line with triangles; liraglutide 1.8 mg: black dotted 
line with squares; rosiglitazone: grey solid line with circles; placebo: black solid line with circles. (d) liraglutide 0.6 mg: black stripes on white; liraglutide 
1.2 mg: white stripes on black, liraglutide 1.8 mg: grey tint; rosiglitazone: white; placebo: black. ****P < 0.0001 compared with placebo; 
††††P < 0.0001 compared with rosiglitazone.
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the differences between treatment groups in favour of liraglutide
were similar irrespective of whether subjects were treated
previously with monotherapy or combination therapy. Neither
age, gender nor BMI affected these trends.
Percentage reaching an HbA1c < 7.0% and ≤ 6.5%
The percentage of subjects reaching ADA [2] and International
Diabetes Federation (IDF)/American Association of Clinical
Endocrinologists (AACE) [11,12] treatment HbA1c goals with
liraglutide was dose dependent (Fig. 4). At week 26, 42% and
21% of subjects treated with liraglutide 1.8 mg reached an
HbA1c < 7.0% and ≤ 6.5%, respectively, compared with 8%
and 4% for placebo (Fig. 4). The estimated proportion of
subjects treated with either liraglutide 1.2 or 1.8 mg reaching
ADA/EASD and IDF/AACE HbA1c targets was substantially
greater compared with either placebo (P < 0.0001) or rosiglita-
zone (Fig. 4; P ≤ 0.0003), with more patients reaching < 7.0%
with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).
Fasting plasma glucose
By week  2, subjects treated with liraglutide had rapid and
larger decreases in FPG vs. comparator treatment. At week 26,
all doses of liraglutide decreased FPG more than did placebo
(Fig. 5; P < 0.0001), while only liraglutide 1.2 or 1.8 mg pro-
duced greater reductions than rosiglitazone. FPG treatment
differences to placebo were 1.7 mmol/l for liraglutide 0.6 mg
and 2.6 mmol/l for both liraglutide 1.2 and 1.8 mg. An 0.7-
mmol/l greater reduction in FPG was achieved with either
FIGURE 4 Subjects achieving specified glycated haemoglobin (HbA1c) levels: (a) percentage reaching HbA1c < 7.0% (American Diabetes Association/
European Association for the Study of Diabetes target); (b) percentage reaching HbA1c < 6.5% (International Diabetes Federation/American 
Association of Clinical Endocrinologists targets); (c) cumulative distribution of HbA1c at 26 weeks for the intent-to-treat (ITT) population; and (d) for 
the ITT last observation carried forward (LOCF) population. Keys: (a, b) liraglutide 0.6 mg: black stripes on white; liraglutide 1.2 mg: white stripes on 
black, liraglutide 1.8 mg: grey tint; rosiglitazone: white; placebo: black. (c, d) liraglutide 0.6 mg: pale grey solid line; liraglutide 1.2 mg: grey solid line, 
liraglutide 1.8 mg: black solid line; rosiglitazone: dotted black line; placebo: dotted grey line; baseline visit: long dashed black line. ****P < 0.0001 or 
**P < 0.01 compared with placebo; ††††P < 0.0001 or †††P = 0.0005 compared with rosiglitazone.
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liraglutide 1.2 or 1.8 mg compared with rosiglitazone (P ≤ 0.006)
after 26 weeks.
The percentage of subjects achieving FPG values between
5.0 mmol/l and ≤ 7.2 mmol/l (ADA target) after 26 weeks was
higher with liraglutide: 0.6  mg (19%; P = 0.002);  1.2 mg
(37%;  P <  0.001); and 1.8  mg (38%; P  < 0.001)  compared
with placebo (7%). The liraglutide 1.2 and 1.8 mg treatment
groups also had more subjects achieving the same FPG target
at end of treatment compared with rosiglitazone (26%)
(P = 0.007 and P = 0.01, respectively).
Postprandial plasma glucose
PPG was reduced similarly after each meal. The greatest
reductions in mean PPG values from baseline (average of
values obtained 90 min after breakfast, lunch and evening
meal) occurred with liraglutide 1.2  mg (2.5  mmol/l) and
liraglutide 1.8 mg (2.7 mmol/l). By comparison, the reduction
from baseline in mean PPG values was 1.8 mmol/l for rosigli-
tazone and liraglutide 0.6 mg and 0.4 mmol/l for placebo.
Treatment differences for PPG were greater with all doses
of liraglutide compared with placebo (1.5–2.4  mmol/l;
P < 0.0001) and greater with liraglutide 1.2 mg (0.64 mmol/l;
P = 0.043) and 1.8 mg (0.87 mmol/l; P = 0.0022) compared
with rosiglitazone.
PPG measurements < 10.0 mmol/l
The percentage of subjects with one, two or three PPG
measurements < 10.0 mmol/l (ADA target) were greater for all
doses of liraglutide compared with placebo (P < 0.05) but not
rosiglitazone.
Body weight
Mean weight at baseline was 81.6 kg. Mean reductions in
weight from baseline to end of treatment were 0.2 kg with
liraglutide 1.8 mg and 0.1 kg with placebo treatment, while
increases occurred with either liraglutide 0.6  mg (0.7  kg),
liraglutide 1.2 mg (0.3 kg) or rosiglitazone (2.1 kg) (Fig. 6).
Unlike rosiglitazone, weight did not increase substantially
with liraglutide and the differences between rosiglitazone and
liraglutide were statistically significant (−2.3 to −1.4 kg;
P <  0.0001), although there were no significant differences
compared with placebo. Gender appeared to have no influence
on the results, as indicated when added as a fixed effect in the
ANCOVA model.
Indices of pancreatic B-cell function and insulin resistance
Reductions in the proinsulin : insulin ratio were greater with
both liraglutide 1.2 and 1.8 mg compared with either rosigli-
tazone or placebo (Table  2; P ≤  0.02). HOMA-B increased
with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone
(P < 0.05), while this increase was only different to placebo
with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg
(P =  0.051). There were no significant differences between
treatments for HOMA-IR.
Blood pressure and pulse
Although decreases in systolic blood pressure occurred with
either liraglutide 1.2 or 1.8 mg (2.6–2.8 mmHg), they were
not significantly different from placebo or rosiglitazone (0.9–
2.3  mmHg). Reductions in diastolic blood pressure also
occurred with all treatments (0.7–1.4 mmHg), with no signif-
icant differences between treatments. Pulse increases above
baseline ranged from 2 to 4 beats/min with the three doses of
liraglutide and 1  beat/min with rosiglitazone, while pulse
decreased by 1 beat/min with placebo. Changes in pulse for all
FIGURE 5 Mean changes from baseline in fasting plasma glucose after 
26 weeks of treatment. ****P < 0.0001 compared with placebo; 
††P < 0.01 compared with rosiglitazone. FIGURE 6 Mean changes in body weight from baseline after 26 weeks of 
treatment. *P < 0.05 compared with placebo; ††††P < 0.0001 compared 
with rosiglitazone.
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doses of liraglutide were significant vs. placebo (P ≤ 0.002).
This also was true with either liraglutide 1.8 or 1.2 mg com-
pared with rosiglitazone (P < 0.01).
Safety
The most common treatment-emergent AEs that were con-
sidered by investigators to be either possibly or probably
related to liraglutide were gastrointestinal (diarrhoea, nausea,
dyspepsia and constipation) and nervous system disorders
(headache and dizziness), particularly during the first 4 weeks.
Nausea was highest with liraglutide 1.2 mg (10.5%) and lowest
with placebo (1.8%). Vomiting (4.4%) and diarrhoea (7.9%)
were also higher with liraglutide 1.2 mg. Withdrawals because
of nausea ranged from 0.9–2.2%, vomiting 0.4–0.9% and
diarrhoea 0–1.3%.
Nausea was more common with liraglutide compared with
placebo and rosiglitazone, particularly during the first 4 weeks
(Fig. 7). Frequency of nausea was less in the liraglutide 0.6 mg
treatment group compared with the higher doses of liraglutide.
Generally, the occurrence of nausea dissipated from 4 to
26 weeks of treatment in all groups using liraglutide (Fig. 7).
The incidence of serious AEs ranged between 3 and 5%:
placebo (3%), rosiglitazone (3%), liraglutide 0.6 mg (3%),
liraglutide 1.2 mg (4%) and liraglutide 1.8 mg (5%). Most
treatment-emergent serious AEs were judged by investigators
to be unlikely to be related to trial products. No deaths were
reported during the trial. One subject developed chronic
pancreatitis whilst taking liraglutide 0.6 mg; the person had no
reported previous history of pancreatitis. The subject continued
on liraglutide therapy and completed the trial. At screening,
five patients had been previously diagnosed with pancreatitis.
As pancreatitis was not an exclusion criterion, these patients
were randomized as follows: one to liraglutide 0.6 mg, one to
liraglutide 1.2  mg, two to liraglutide 1.8  mg and one to
rosiglitazone  +  glimepiride. All five patients completed the
trial without reporting pancreatitis as an adverse event.
Hypoglycaemia was infrequent with all treatments. One
major hypoglycaemic episode (self-measured blood glucose =
3.0 mmol/l) occurred 9 days after treatment started in a
subject receiving liraglutide 1.8  mg in combination with
glimepiride. Although medical assistance was not needed, the
subject required third-party assistance. The investigator
judged the episode as likely to be related to glimepiride and
reduced the dose from 4 to 3 mg after the incident.
Minor hypoglycaemia occurred in < 10% of subjects for any
treatment. The proportion of subjects experiencing minor
hypoglycaemia during the trial was lowest with placebo (i.e.
glimepiride monotherapy 2.6%; 0.17 events/subject-year),
comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-
year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups
and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/
Table 2 Selected indices of pancreatic B-cell function
Variable Treatment Baseline
Week 26 
(LOCF)
Least square difference 
from placebo (95% CI)
Least square difference 
from rosiglitazone (95% CI)
Proinsulin : insulin ratio Liraglutide 0.6 mg 0.42 ± 0.22 0.38 ± 0.24 −0.05 (−0.11; 0.00) −0.02 (−0.06; 0.03)
Liraglutide 1.2 mg 0.45 ± 0.31 0.33 ± 0.20 −0.10 (−0.16; −0.05)† −0.07 (−0.11; −0.02)*
Liraglutide 1.8 mg 0.48 ± 0.33 0.36 ± 0.20 −0.09 (−0.15; −0.03)* −0.05 (−0.10; −0.01)*
Placebo 0.44 ± 0.27 0.46 ± 0.29
Rosiglitazone 0.45 ± 0.29 0.40 ± 0.20
HOMA-B (%) Liraglutide 0.6 mg 51 ± 43.3 70 ± 88.6 15 (−19.10; 49.0) 11 (−16.7; 39.0)
Liraglutide 1.2 mg  71 ± 254.3 99 ± 184.3 43 (8.10; 76.9)* 39 (10.3; 67.0)*
Liraglutide 1.8 mg 56 ± 84.6 91 ± 108.2 34 (−0.23; 68.5) 30 (2.00; 58.6)*
Placebo 56 ± 103.3 52 ± 107.3
Rosiglitazone 46 ± 36.2 59 ± 63.3
*P ≤ 0.05; †P < 0.0001.
CI, confidence interval; HOMA, homeostatis model assessment; LOCF, last observation carried forward.
FIGURE 7 Percentage of subjects experiencing nausea over the course of 
the study. Key: liraglutide 0.6 mg with glimepiride: black line with filled 
circles; liraglutide 1.2 mg with glimepiride: black line with filled 
triangles; liraglutide 1.8 mg with glimepiride: grey line with hollow 
circles; glimepiride grey lines with filled squares; rosiglitazone and 
glimepiride: grey line with hollow triangles.
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subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-
year) treatment groups. Incidence was higher with liraglutide
1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with
rosiglitazone and liraglutide 1.2 mg compared with placebo
(P = 0.048), occurring in the setting of lower mean HbA1c values.
Antibodies to liraglutide were found in 9–13% of subjects
treated with liraglutide. No significant effects of these antibodies
on HbA1c were found in pooled analyses of four trials including
the current study. There were no clinically relevant changes in
ophthalmoscopy, biochemistry, urinalysis, haematology or
ECG assessments. No significant differences in calcitonin were
found between the three groups treated with liraglutide when
compared with either placebo or rosiglitazone at the end of the
trial at week 26.
Discussion
Treatment with liraglutide plus glimepiride was superior to
glimepiride monotherapy at all doses of liraglutide and
superior to rosiglitazone plus glimepiride for the two higher
liraglutide doses for improving HbA1c. Similar findings for
reductions in FPG and PPG highlight improved 24-h glucose
control with once-daily liraglutide, with substantially more
subjects reaching glycaemic targets, particularly with liraglutide
1.8 mg. Improvements in pancreatic B-cell function were larger
with liraglutide 1.2 and 1.8 mg compared with rosiglitazone.
Liraglutide was well tolerated and occurrence of gastrointestinal
AEs was low overall, particularly after week 4.
Although rates of hypoglycaemia were low in all treatment
groups (< 10%), minor hypoglycaemic events occurred more
often in patients treated with glimepiride plus liraglutide 1.2 or
1.8 mg than with glimepiride alone. It should be noted, how-
ever, that patients treated with liraglutide 1.2 or 1.8 mg achieved
a lower HbA1c than those receiving glimepiride monotherapy.
At lower HbA1c levels, sulphonylureas are known to elicit
hypoglycaemia more readily than at higher levels. In clinical
practice it may be possible to reduce the dose of sulphonylurea
(when used with liraglutide) to minimize risk of hypoglycaemia
and maintain HbA1c improvements.
Although weight effects were modest, liraglutide produced
more favourable weight effects compared with rosiglitazone,
which produced substantial weight gain. In other studies with
liraglutide, subjects adding a 1.8-mg dose to metformin lost
2.8 kg [14], while those adding both metformin and glimepiride
lost 1.8 kg compared with placebo [15] (both over 26 weeks)
and those on liraglutide monotherapy (1.8 mg) lost 2.45 kg
over 52 weeks [16]. In our study, because sulphonylureas usually
cause weight gain, inclusion or optimization of glimepiride but
not metformin may have mitigated the weight benefits typically
associated with liraglutide. Lack of weight effects could be
secondary to lower baseline body weight, withdrawal of previous
metformin treatment or defensive snacking to minimize risk of
hypoglycaemia.
It might have been expected that the greater weight gain
with rosiglitazone compared with liraglutide 1.8 mg would be
associated with a concurrent increase in insulin resistance with
rosiglitazone. The absence of this effect could reflect the insulin-
sensitizing nature of rosiglitazone. Improvements in pancreatic
B-cell function associated with liraglutide are consistent with
other studies [7–9].
Study strengths include inclusion of both placebo and active
(rosiglitazone) comparators and that OGLAs were optimized
(not maximized) before randomization to minimize risk of
hypoglycaemia. Limitations of the study include short duration
of the trial and restriction on glimepiride and rosiglitazone
in some countries that precluded maximal dosing.
The impact of using other GLP-1-based treatments [such as
exenatide, or the dipeptidyl peptidase-4 (DPP-4) inhibitor,
sitagliptin] with sulphonylureas in subjects with T2D has been
studied. In a 30-week American trial where exenatide twice a
day was added to sulphonylureas, HbA1c  was reduced by
0.46% from baseline with 5 µg and 0.86% with 10 µg [17]
compared with 1.1% with liraglutide 1.8 or 1.2  mg. This
reduction in HbA1c with liraglutide is consistent with other
LEAD trials investigating liraglutide as monotherapy or in
combination with various OGLA drugs. In these trials, HbA1c
was reduced by 1–1.5% [14,16,18–20]. Reductions in FPG
with exenatide were 0.3 and 0.6 mmol/l from baseline with
5 µg and 10 µg, respectively, compared with 1.4 mmol/l with
liraglutide 1.8 mg; weight loss of 1.6 kg occurred with exenatide
10 µg compared with 0.2 kg for liraglutide 1.8 mg [17].
Differences in weight effects may be as a result of lower baseline
weight in this trial (82 kg) compared with exenatide (96 kg)
and discontinuation of previous metformin therapy, unlike the
exenatide trial where exenatide was added to previous sulpho-
nylurea monotherapy [17]. Other large-scale trials with liraglutide
in combination with sulphonylureas have demonstrated weight
loss of 2–3  kg [18,20]. Withdrawals from exenatide trials
ranged from 24–30% compared with 9–14% with liraglutide
in this study. Nausea with exenatide ranged from 39% with
5 µg to 51% with 10  µg [17] compared with 10.5% for
liraglutide. Furthermore, 41% were positive for anti-exenatide
antibodies compared with 9–13% with anti-liraglutide antibodies.
With sitagliptin 100 mg once daily for 24 weeks, HbA1c
decreased by 0.3% from baseline in subjects receiving glimepiride,
with 11% achieving an HbA1c <  7.0% [21]. Reductions in
FPG and PPG from baseline were 0.05 and 1.4 mmol/l, respectively,
while weight increased by 0.8 kg and the prevalence of nausea
was < 1%.
Although head-to-head trials are required to test true differences
between these agents, the marked effects of liraglutide on FPG
may be as a result of consistent blood levels of liraglutide main-
tained over 24 h compared with exenatide which has to be
administered 60 min before breakfast and dinner and has a
half-life of 1.5–3.6 h [22]. In a recent 26-week head-to-head
trial comparing liraglutide with exenatide, liraglutide produced
a 0.3% greater decrease on HbA1c (P < 0.0001) [20]. Because
DPP-4 inhibitors inhibit the degradation of GLP-1, the efficacy
of sitagliptin is dependent on levels of endogenous GLP-1
which is physiologically low compared with the much higher
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pharmacological levels of liraglutide. Pharmacological levels
may be needed to induce satiety, weight loss and possibly
larger HbA1c reductions.
Liraglutide is an effective and well-tolerated once-daily human
GLP-1 analogue that improves overall glycaemic control
and indices of pancreatic B-cell function with minimal weight
gain and risk of hypoglycaemia when used in combination
with a sulphonylurea for T2D.
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